Dr. Sumathi Poleboina

Assistant Professor

Work Experience

3 years

Area of Specialization

Pharmacology

Projects & Patents

NA

Education

M.S (Pharm), Ph.D.

Achievments/Awards/Honors

 2023: Received Best Oral Presentation Award in International Conference on Nanopharmaceuticals on neurological disorders (ICNAND23), IGNTU, Madhya Pradesh  2016-22: Received Research Fellowship (CSIR-SRF(NET)) for PhD studies in Pharmacology and Toxicology from NIPER-S.A.S Nagar  2012-14: Received Research Fellowship for M.S (Pharm) in Pharmacology and Toxicology from NIPER-Guwahati  2015: Qualified CSIR-NET (JRF) 2 times in Life Sciences  2015: Qualified GATE EXAM in Life sciences  2014: Qualified CSIR- NET (Lectureship) in Life Sciences  2012: Qualified NIPER and GPAT

Publications

Development of HFD-Fed/Low-Dose STZ-Treated Female Sprague-Dawley Rat Model to Investigate Diabetic Bone Fragility at Different Organization Levels. Centre: School of Natural Resources Department: Pharmacy Phone: 09440426884 Mail: sumathipoleboina@gmail.com Personnel Web Page Link: Nil Praveer Sihota, Ram Naresh Yadav, Sumathi Poleboina, Vishwajeet Mehandia, Sanjay Kumar Bhadada, Kulbhushan Tikoo, and Navin Kumar. JBMR PLUS. Volume-4, Issue-10, 2020 page no: e10379, IF-6.741, doi: 10.1002/jbm4.10379, Published.  Selenium nanoparticles prevent diabetic osteoporosis by initiating osteoblast differentiation and bone formation via BMP-2/MAPKs/β-catenin pathway. Sumathi Poleboina, Vaibhav G Sheth, Nisha Sharma, Praveer Sihota, Navin Kumar and Kulbhushan Tikoo. Nanomedicine, Volume-17, Issue-9, 2022, page no: 607-625, IF-5.307, doi: 10.2217/nnm-2021-0401, Published.  Gold nanoparticles suppress RANKL induced osteoclastogenesis in RAW 264.7 cells by inhibiting NF-κB signaling pathway and preventing Ovariectomy-induced bone loss in female SD rats. Sumathi Poleboina and Kulbhushan Tikoo Nanomedicine: Nanotechnology, Biology, and Medicine (Under review), Impact Factor (6.458). Nanomedicine.